Recent Winners


+180%
PLX
Alert Price: $0.36
High Price: $1.01
Results: 180% in 40 Days
+157%
OREX
Alert Price: $1.81
High Price: $4.65
Results: 157% in 36 Days
+91%
GBT
Alert Price: $15.85
High Price: $30
Results: 91% in 41 Days
+87%
ARIA
Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
+58%
XGTI
Alert Price: $1.47
High Price: $2.32
Results: 58% in 29 Days
+55%
EXAS
Alert Price: $15.10
High Price: $23.40
Results: 55% in 37 Days
+38%
EDIT
Alert Price: $18.24
High Price: $25.09
Results: 38% in 55 Days
+36%
CYNO
Alert Price: $48.25
High Price: $65.90
Results: 36% in 28 Days
+32%
EBS
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
+27%
ICHR
Alert Price: $13.40
High Price: $17.04
Results: 27% in 22 Days
+23%
CNAT
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
+23%
PEIX
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
+21%
KATE
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
+20%
REPH
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
+20%
SN
Alert Price: $11.24
High Price: $13.46
Results: 20% in 15 Days
+16%
CX
Alert Price: $7.97
High Price: $9.30
Results: 16% in 10 Days
+16%
ACAD
Alert Price: $32.03
High Price: $37.09
Results: 16% in 26 Days
+15%
PVG
Alert Price: $7.17
High Price: $8.24
Results: 15% in 6 Days
+12%
OCLR
Alert Price: $8.49
High Price: $9.55
Results: 12% in 7 Days
+12%
ACET
Alert Price: $19.50
High Price: $21.93
Results: 12% in 26 Days
+12%
COW
Alert Price: $20.00
High Price: $22.42
Results: 12% in 26 Days
+11%
PLKI
Alert Price: $70.82
High Price: $79
Results: 11% in 5 Days
+10%
HWKN
Alert Price: $48.15
High Price: $52.90
Results: 10% in 14 Days
+9%
LLY
Alert Price: $67.61
High Price: $73.56
Results: 9% in 12 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.

Trading Lessons

Mainstream Financial News

Archives

Jazz Pharmaceuticals Announces Positive Results From Phase 3 TONES 3 and TONES 4

March 20, 2017: Jazz Pharmaceuticals announced positive efficacy results from two global multicenter studies in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA). JZP-110 demonstrated highly statistically significant differences in the co-primary efficacy endpoints in the TONES 3 study at the 300 mg, 150 mg, 75 mg and 37.5 mg dose arms (Read More….)

UBS Initiates Vertex With Buy Rating

March 9, 2017: UBS initiates Vertex Pharmaceuticals Inc with a Buy rating and a price target of $106. UBS is launching coverage of US Biotechnology with a positive outlook buoyed by (1) a better line-up of drug launches for 2017 (Biogen’s Spinraza for SMA; Regeneron’s Dupixent for atopic dermatitis, and Incyte’s Olumiant for rheumatoid arthritis), (Read More….)

Top Performing GuerillaStockTrading Stocks For the Week Ending March 3 2017

GBT exploded into position #1 gaining 31% last week. Nomura initiated coverage of GBT with a Buy rating and a price target of $50. Let’s go ahead and book profits on Monday if you haven’t already. Remember folks, sell into strength and don’t wait for me to issue a sell signal before cashing out and (Read More….)

Sell Exact Sciences For a 55% Win!

March 4, 2017: Sell Exact Sciences for a 55% win in 37 days. Congratulations if you were able to make money on the trade and always remember to sell your positions before you get the sell alert from me. I review more than 200 open stock positions over the weekend when I have time and (Read More….)

LightPath Technologies Beats on Earnings and Revenue

February 15, 2017: Lightpath Technologies reports Q2 EPS of $0.06 versus the $0.02 estimate. Revenue also beat coming in at $5.9 million versus the $5 million estimate.

December 22, 2016: Roth Capital initiates coverage of LightPath Technologies with a Buy rating, and a price target of $2.50. Roth Capital thinks LightPath is a business that (Read More….)

Sarepta Therapeutics Candle Over Candle On Feuerstein

February 14, 2017: Sarepta Therapeutic’s stock has formed a candle over candle reversal after Feuerstein said, “Sarepta Therapeutics is being dragged down unfairly into the price-gouging muck by Marathon Pharmaceuticals.” Source: https://www.thestreet.com/story/14001431/1/defending

January 10, 2017: Baird reiterates a Buy rating on biotechnology firm Sarepta Therapeutics and set a price target of $102. Baird named Sarepta (Read More….)

JP Morgan Makes Positive Comments on Gilead Sciences

February 14, 2017: JP Morgan making positive comments about Gilead Sciences, reiterates their Overweight rating. JP Morgan says that ahead of a presentation today at CROI (2/13-17, Seattle), GILD released the anticipated results from the Phase 2 trial evaluating its novel unboosted integrase inhibitor bictegravir (BIC) vs. ViiV’s dolutegravir (DTG) in treatment naive HIV patients (Read More….)

Mylan Investors Shrug Off $96.5 Million Settlement

February 6, 2017: Mylan stock got my attention today because the stock climbed on the news that Mylan has to pay $96.5 million in settlement of the Provigil antitrust class action suit. The settlement covers allegations that Mylan delayed launching its generic version of Cephalon narcolepsy drug Provigil in exchange for payment from Cephalon. The (Read More….)

Regeneron Pharmaceuticals Gets Approval of Kevzara With Sanofi For Rheumatoid Arthritis

February 1, 2017: Regeneron Pharmaceuticals, Inc. and Sanofi today announced that Health Canada approved Kevzara™ (sarilumab), an interleukin-6 (IL-6) receptor antibody, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more biologic or non-biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

Kevzara (Read More….)

Maxim Raised ADMA Biologics To Buy

January 23, 2017: Maxim raised ADMA Biologics to a Buy rating. Maxim said ADMA Biologics announced that it will acquire Biotest’s 126,000 square foot immunoglobulin manufacturing facility (where RI-002 is manufactured) as well as two FDA-approved immunoglobulin assets (BIVIGAM and Nabi-HB). When the deal closes (April/May 2017), ADMA Biologics will become a fully integrated plasma (Read More….)

AbbVie Gets FDA Approval For Imbruvica

January 19, 2017: AbbVie announced that the U.S. Food and Drug Administration (FDA) approved IMBRUVICA (ibrutinib) for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. This indication is approved under accelerated approval based on overall response rate (ORR), and (Read More….)

Huron Consulting Group Oversold Doji On Acquisition of Pope Woodhead & Associates

January 9, 2017: Huron Consulting Group formed a doji today, in oversold territory, on news it acquired Pope Woodhead & Associates. Huron Consulting Group says that it has expanded its life sciences strategy expertise with the acquisition of Pope Woodhead & Associates. The UK-based consulting firm provides market access capabilities to assist clients in developing (Read More….)

ARIAD Pharmaceuticals Sell For 86.7% Win!

January 9, 2017: Sell ARIAD Pharmaceuticals on the news that it will be acquired by Takeda for $24 per share. This was a monster 86.7% win for us. Congratulations if you were able to make money on the trade.

January 4, 2017: Seeing heavy weekly call activity in Ariad Pharmaceuticals: 1,684 Jan 13 $13 (Read More….)

Novartis Alcon Receives FDA Approval For AcrySof

February 28, 2016: Novartis announced that the FDA has approved Afinitor for the treatment of some tumors. The FDA has approved everolimus (Afinitor) for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease. The approval was based on demonstration of improvement in progression-free survival (PFS) in a multicenter, randomized (2:1), placebo-controlled trial of everolimus 10 mg orally once daily plus best supportive care (BSC) to placebo plus BSC. (Read More….)

Eli Lilly Sell For 8.8% Win In 12 Days

December 29, 2016: Sell Eli Lilly for an 8.8% gain in 12 trading days. Congratulations if you were able to make money on the trade.

December 16, 2016: Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro in people with Type 1 diabetes. This is a successful completion of an (Read More….)

Tonix Pharmaceuticals J Hook Bottom On Breakthrough Therapy Designation

December 28, 2016: Tonix Pharmaceuticals is forming a wide J Hook pattern after having the FDA granted their PTSD drug TNX-102 a Breakthrough Therapy designation.

December 19, 2016: Tonix Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy designation to TNX-102 SL for the treatment of posttraumatic stress disorder (Read More….)

Analyst Actions and Breaking News

Overnight Analyst Actions:

Raised:

REGN Outperform Credit Suisse First Boston TECK Outperform Macquarie

Initiates:

TECK Buy MKM Partners

Cuts:

AMGN Neutral Credit Suisse First Boston

Overnight Headlines By Ticker:

AMGN   Amgen Inc

12/20   08:21   Credit Suisse Cuts AMGN to Neutral from Outperform, price target: $180

12/19 (Read More….)

Editas Medicine Rising Twiggs Money Flow

Editas Medicine has an explosive Twiggs Money Flow on the chart.

Editas Medicine is a risky biotechnology stock with no P/E.

The catalyst is none other than the Biotech Discovery of the Century. Yeah, that sounds like major hype and maybe somebody is drinking the Kool-Aid. Nevertheless, the chart looks pretty sweet with the (Read More….)